Glenmark announced the upcoming launch of Eribulin Mesylate Injection in the U.S. this Sept, the first of its complex generics, tapping into the USD 66.3M oncology market. Glenmark Pharmaceuticals Inc., USA, is a subsidiary of Glenmark Pharmaceuticals Ltd. Eribulin Mesylate Injection is formulated in 1 mg/2 mL (0.5 mg/mL) single-dose vials. The distribution will begin in September 2025, marking a major addition to its institutional benchmark.
This initiative of Eribulin Mesylate Injection will strengthen Glenmark’s U.S. footprint in the oncology and institutional space. With its proven equivalence to Halaven® as well as a sizeable market opportunity, this move demonstrates Glenmark’s ability to deliver value to patients while driving growth in complex generics.
Eribulin Mesylate Injection is bioequivalent and therapeutically equivalent to the reference listed drug Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), marketed by Eisai, Inc. This ensures patients can access a cost-effective as well as reliable alternative to the branded therapy. Along with that, the entry of Glenmark into this segment represents the strategy of the company targeting complex generics with strong growth potential.
Glenmark's portfolio in the oncology environment with this complex generic reflects a growing trend of pharmaceutical companies making their way towards high-barrier markets to deliver cost-effective treatments. In line with this, by adopting its established U.S. distribution network along with institutional relationships, the company expects to navigate regulatory and supply-chain challenges efficiently.
Executive Statement
According to Marc Kikuchi, President & Business Head, North America, this launch marks their commitment to expanding the institutional product portfolio and reinforces our mission to provide affordable alternatives for patients in need. This also represents Glenmark’s first complex generic launch in the U.S., underlining its focus on innovation and market expansion.